Shots: Onconova to receive $25.55M as clinical, regulatory and commercialization milestones and royalties on sales of Rigosertib. Knight therapeutics to receive exclusive rights to commercialize Rigosertib in Canada If approved, […]readmore
Tags : Onconova
Shots: Onconova to receive e $6M upfront including $2M cash, $2M shares & $2M as escrow funding with $45.5M regulatory, development & commercial milestones and royalties on sales. HanX to […]readmore